A secrecy bill that would have rendered confidential information about the source of the state’s execution drugs stalled earlier this year in Louisiana’s Senate judiciary committee following engagement by pharmaceutical industry leaders.
HB258 was intended to enable state officials to obtain execution drugs under cover of secrecy, breaching the contractual controls companies have enacted to prevent the sale of their medicines for this purpose.
Secrecy laws frustrate healthcare companies’ efforts to effectively monitor the distribution of medicines to prevent drug diversion and public health crises.
Read more about state secrecy laws and the implications for commercial enterprises here.
Read more about the public health implications stemming from death rows’ efforts to obtain lethal injection drugs in an amicus brief filed by Pharmacy, Medicine, and Health Policy Experts in the US Supreme Court Case of Bucklew v Precythe here.
Read more about the pharmaceutical industry’s opposition to the misuse of medicines in executions in an amicus brief filed by the Association for Accessible Medicines in the US Supreme Court Case of Bucklew v Precythe here.